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Measles virus (Rubeola)
The first written description of measles attributed to 
Abu Becr Rhazes in the 10th century. He referred to 
measles as Hasbah, which means eruption in Arabic, but 
the viral aetiology of measles was not confirmed until 
1911 by Anderson and Golderger [1]. 
Measles virus is a member of the genus Morbilli virus 
in the family paramyxoviridae, which is a linear single 
strand RNA [2].
Measles is known as one of the most infections and per-
sistent of human viral diseases. Its distribution is world-
wide and it causes disease in any climate and under 
any condition provided that enough susceptible human 
beings are brought together to enable its spread [3]. Hu-
mans are the only natural host for measles virus with no 
animal reservoirs or vectors involved [4]. The principal 
mode of transmission is via droplet infection. Indirect 
contact and transmission by fomites may also occur. 
Patients are considered to be infectious from the onset 
of symptoms through the 4th day of rash [1], with no 
evidence that measles infections can occur twice [5].
In many developing countries measles is still the most 
important cause of death between the ages of one and 
five years [6].
Trends of measles
In the populous areas of the world measles causes epi-
demics every two to five years. Meanwhile, in the large 
villages and semiurban populations in the developing 
world epidemics occur every two to three year [7]. 
However, in the rapidly expanding urban conglomera-
tion in the developing world, the continuos immigration 
from the original population provides a constant influx 
of susceptible individuals and in turn a sustained oc-
currence of measles and unclear epidemics. Measles 
in developing countries occurs at a much younger age 
compared with developed countries. In some area of Af-
rica more than 50% of children may be infected before 
the age of two years and nearly 100% by the age of five 
years [1].
Countries in which measles vaccine is widely used like 
United States have experienced a marked decrease in 
the incidence of the disease. There was also concomitant 
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shift in the age specific incidence to a higher age [8]. 
In developed countries measles epidemics are closely 
tied to the school years, building up to a peak in the 
late spring and ceasing abruptly after the summer has 
begun.
In Africa measles epidemics usually begin in the mid-
dle of the dry season and decline with the onset of the 
wet season. The difference in pattern from one area to 
another presumably is related to population dynamics 
and habits [7].
Measles vaccines
Numerous attempts have been made to device an effec-
tive and harmless mean for the artificial induction in 
man of active immunity against measles. In March of 
1963 two measles vaccines were licensed for general 
use, live attenuated measles vaccine (Edmonston “B” 
type) and killed virus vaccine. The Edmonston “B” 
strain vaccine produced good levels of immunity but 
frequently caused high fever and rash about seven to ten 
days after immunisation [9].
By the time it was apparent that the immunogenic and 
protective effects of inactivated measles virus vaccine 
were transient. Therefore, killed vaccine was withdrawn 
from market in 1968 and is no longer available for 
use [10].
In Egypt, Hosney et al. (1964) used the killed measles vi-
rus vaccine as the first trial of measles vaccination [11]. 
Then Imam et al. (1965) used the live attenuated mea-
sles (Edmanston “B” strain), and since then measles 
vaccine has been used in Egypt [12]. Measles vaccine 
coverage by live attenuated vaccine (Schwarz vaccine) 
in Egypt had reached over 90% by year 1994 [13].
In the United States in 1971, a combined vaccine incor-
porating attenuated measles, mumps and rubella virus 
in one product was licensed and this trivalent product 
soon became the vaccine of choice providing with a 
single injection successful immunisation against all 
three infections. The combination showed no reduction 
in immunogencity or efficacy of the individual compo-
nents [6].
Live attenuated measles virus vaccine is usually admin-
istrated before the age of 1 year. It is available as freeze 
dried preparation, stored at 4oC. This vaccine is heat and 
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light sensitive and this constitute the major problem. 
Poor storage condition results in loss of vaccine potency 
particularly in less developed countries where mainte-
nance of a reliable cold chain is often difficult [14, 15].
In 1970 attention focused on the “Edmonston Zegreb” 
EZ vaccine produced in Yugoslavia. This vaccine pos-
sesses the potential to immunise infants successfully 
at a younger age [16]. Studies suggested that the “Ed-
monston Zegreb” EZ vaccine given at 4-6 months may 
provide more protection than the Schwarz vaccine given 
at 9 months [17, 18].
Measles vaccination policy
Measles maternal antibody persists in the infant for 
most of the first year of life. This antibody interferes 
with the response to measles vaccine. Clearly then it 
is better to delay vaccination until after the end of the 
first year. In developing countries where measles is 
endemic, the recommended age of measles vaccination 
has been estimated at 9 months. At this age measles 
maternal antibody has usually fallen to low level and 
vaccination of infants may give a seroconversion rate of 
80% [3, 19-22].
In Egypt, the Expanded Programme of Immunization 
first recommended a single dose of live attenuated vac-
cine (Schwarz vaccine) at the age of 9 months [13]. In 
1997 a retrospective case control study in two primary 
schools located in Cairo was conducted to evaluate the 
protective value of routine measles vaccination. The 
overall measles vaccine effectiveness was estimated at 
53% (95% CI 71%-26%), and there was an association 
between age of measles vaccination and vaccine effec-
tiveness. Vaccination failure due to young age of mea-
sles vaccination was the likely explanation of the low 
measles vaccine effectiveness. This study recommended 
the adoption of two-dose measles vaccination policy 
with the second dose being given at older age [23]. 
The Expanded Programme of Immunization of Egypt 
2 years later recommended a second dose of Schwarz 
vaccine at the age of 18 months [24].
Until 20 years ago, in the developed world, measles 
vaccine was given to children in their second year after 
the age of 15 months [25] as one dose, but Sweden and 
Finland has already given a second dose several years 
after the first [26].
USA has adopted a two-dose policy and this strategy 
was the recommendation of the 1989 Meeting National 
Program Managers to all European Member States. The 
rationale for a two-dose policy is to assure the highest 
possible level of immunity [27]. This recommendation 
matches with results obtained following an outbreak 
of measles in a primary school in the Australian ca-
pital territory in September 1993 where there was no 
increased risk of measles infection in those who had 
been immunised under 15 months of age compared with 
those immunised at 15 months or older. Also none of the 
children who had received two-dose of vaccine caught 
measles [28].
Following a large measles outbreak during 1992 in 
oman with total of 562 cases the out-line immunisa-
tion schedule was modified into two doses of measles 
vaccine; a dose of signal antigen measles vaccine at 9 
months, and a dose of MR (Measles, Rubella) vaccine 
at 15 months [29].
In United Arab Emirates the plan of action for the 
elimination of indigenous transmission of measles in-
cludes the administration of 2 doses of measles vaccine 
in the routine schedule at 9 months and 15 months of 
age and emphasises the importance of increasing the 
immunisation coverage to a level that exceeds 95% of 
all infants [30].
Effectiveness of measles vaccine
Similar to immunity after natural infection, live measles 
vaccine induced immunity has been thought to be life 
long [14, 31]. Reyes (1987) reported that seroconver-
sion is an indicator of measles vaccine efficacy. Failure 
to seroconvert could be due to primary	vaccine	failure	
which is generally attributed to neutralisation of the at-
tenuated vaccine virus by persistent maternal antibody 
in infants younger than 12 months of age or to inade-
quate immunisation as a consequence of bad storage 
conditions and handling or secondary	 vaccine	 failure 
which refers to the development of clinically apparent 
measles infection despite an immune response to initial 
vaccination. The elected response may be inadequate 
to protect against the subsequent inoculum of wild type 
virus or an initially protective response may wane over 
time [32].
Vaccine efficacy tells us what proportion of children is 
protected by immunisation against a disease. Measles 
vaccine under ideal condition has a high efficacy (about 
90%). According to WHo 1989 reports, a vaccine effi-
cacy of 90% means that your program is as effectively 
as possible. Vaccine efficacy of 80- 90% means that 
your program is not as effective as it could be, but there 
is not a major problem.Vaccine efficacy of less than 
80% indicates that there is a problem with the program. 
This could be due to problem with the cold chain, the 
injection technique, or the age at which health workers 
are immunising children, and you should take action to 
correct it [33].
WHo Global Advisory Group (1990) had recommended 
primary vaccination to be at the age of nine months in 
endemic areas to avoid infection at young age [34]. This 
policy also has caused major reductions in incidence of 
measles and its complications but has failed to eradicate 
the disease even in developed countries [22, 35].
In a previous study conducted in Egypt by Khashaba 
(1993), measles antibody titres were shown to decrease 
gradually as time passes after vaccination, but it was 
still protective at age 10-12 years. For those who shown 
a low titre primary rather than secondary vaccine failure 
appears to be responsible for the high failure rate in 
Egypt [36]. This problem continued till changing the 
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vaccine calendar with the administration of a second 
dose at the age of 18 months [24].
Low vaccine effectiveness in developing countries has 
usually been explained in terms of either too young an 
age at vaccination or a poor cold chain [18].
Age of vaccination is considered as the most important 
factor in measles vaccine effectiveness. Effectiveness 
increased from 84% at age 9 months to 100% at 12 mon-
ths in Haiti. Similarly, Effectiveness is from 92.5% at 9 
months to 100% at 12 months in Kenya [37].
Following a large measles outbreak in Quebec City in 
1989, a school-based case-control study was conducted 
to evaluate measles vaccine effectiveness with respect 
to age at vaccination. The relative risks of measles and 
the results showed a trend towards increased vaccine 
efficacy with increasing age at vaccination (P < 0.001). 
Vaccine efficacy elevated from 85% in children vacci-
nated at 12 months of age to equal to or more than 94% 
in those vaccinated at 15 months and older [38].
Similarly in Ivory Coast vaccine effectiveness was 
found to be as low as 56% for children immunised 
around 9 months to a high of 100% among children 
immunised at 15 months or older [39].
In Brazil, vaccine efficacy was only 43% for children 
who received the vaccine around 9 months of age, 
against 83% for those who were immunised later [40].
In N’Djamena, capital of Chad, measles vaccine effi-
cacy was estimated by comparing attack rates in unvac-
cinated and vaccinated children. The result was 71% 
(95% CI: 59-80%) for children vaccinated with a single 
dose of Schwarz vaccine at age 9 months [41].
A lower figure of 54% (95% CI, 36%-67%) was esti-
mated in Dar El Salaam, Tanzania following a case-
control study for evaluating the protective effect of 
measles vaccine under routine vaccination at 9 months 
of age [42]. Similarly the measles elimination campaign 
in the Caribbean recommended that measles vaccine 
should be administrated at 12 months instead of 9 mon-
ths. This would maximise the efficacy but should only 
be done if the attack rate of measles is very low [43].
Low vaccine effectiveness could be explained by the 
presence of maternal antibodies against measles in in-
fants up to 9 months of age. These antibodies interfere 
with the seroconversion to measles vaccine [19].
In Kinshasa, Zaire, vaccination at age 6 months with 
“Edmonston-Zagreb” EZ vaccine was introduced in 
1989. This vaccine achieved over 90% reduction in 
reported measles incidence, with a fall in the proportion 
of cases less than 9 months of age. However, this could 
be attributed to concomitant high coverage with this 
vaccine [44].
In Egypt the age of primary vaccination tended to be at 
the age of 9 months with no booster and this has been 
shown to cause decreased vaccine efficacy. Such fin-
dings draw the attention for the importance of a booster 
dose to assure the highest possible level of immuni-
ty [20, 23].
Primary vaccine failure normally occurs in 2-5% of 
recipients of a single dose measles vaccine, and this 
percentage may be enough to sustain transmission. It is 
anticipated that the second dose will protect 95-98% of 
those who remain susceptible after the first dose [45].
Khashaba et al. (1988) concluded that vaccination befo-
re one year resulted in a significantly lower mean anti-
body titres when compared to infants vaccinated at age 
15 months or later. However, demonstrable antibody 
titres were evident in 15% of the older studied infants 
indicating prior infection. It was therefor recommended 
to give a primary vaccine at 9 months to protect against 
measles infection and to administer a subsequent boo-
ster to ensure higher antibody titres and high serocon-
version rates [36].
This agrees with the recommendations of the Depart-
ment of Health in Australia that announced a two doses 
schedule [45].
Such policy proved successful following an outbreak of 
measles in Australia where none of the children who had 
received two-dose of vaccine caught measles [28].
In Canada, despite that vaccine coverage had reached 
99.7% with one dose of measles vaccine an outbreak had 
occurred among secondary school children. This em-
phasised that similar outbreaks could happen any where 
with current routine one dose schedule. The National 
Advisory Committee of Immunisation recommended a 
second booster dose to avoid such outbreaks [30].
The Centres for Disease Control and Prevention of USA 
(2001), recommended vaccination at 6 months of age 
followed by routine revaccination when exposure of 
infants to measles is likely, especially in areas at high 
risk. Early two-dose measles vaccination was associated 
with improved coverage and a comparably high level 
of humoral immunity and clinical protection as a single 
dose at age ≥ 12 months [46].
The WHo European Region has a measles elimination 
target for 2010. Between September 2005 and mid-June 
2006, more than 50,000 measles cases were reported 
in Ukraine; many reportedly had received two doses 
of measles vaccine and over 60% were among persons 
15-29 years old. To investigate vaccine effectiveness, a 
case-control study was undertaken in Dnepropetrovsk 
region. Vaccine effectiveness for two doses of measles 
vaccine was 93.1%, providing insufficient population 
immunity for measles elimination. An additional dose 
of measles vaccine for these age-cohorts was recom-
mended required if Ukraine is to achieve measles eli-
mination [47].
So et al. (2008) reported a measles outbreak in a pre-
school in Incheon (Korea). The epidemiological investi-
gation of this outbreak showed that the vaccine’s effi-
cacy was 88.8% in the one dose group and 98.0% in the 
two doses group. The authors recommended improving 
the coverage with two doses vaccination [48].
In 2006, a large measles outbreak (number = 614) oc-
curred in Duisburg city, Germany, with 54% of cases 
aged > 9 years. An investigation was launched to de-
termine reasons for the resurgence of measles, assess 
vaccination coverage and vaccine effectiveness. The 
results showed vaccine effectiveness of 98.1% (95% CI: 
92-100%) in students with one and 99.4% (95% CI: 97-
100%) with two measles containing vaccine doses [49].
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